Comparative Pharmacology
Head-to-head clinical analysis: VANTRELA ER versus WELLBUTRIN SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VANTRELA ER versus WELLBUTRIN SR.
VANTRELA ER vs WELLBUTRIN SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Norepinephrine reuptake inhibitor and alpha-2 adrenergic receptor agonist; increases norepinephrine and serotonin availability in the prefrontal cortex.
Wellbutrin SR (bupropion) is an atypical antidepressant. Its mechanism of action is not fully understood, but it is thought to involve inhibition of dopamine and norepinephrine reuptake in the brain, with minimal effect on serotonin reuptake. It also acts as a nicotinic acetylcholine receptor antagonist.
VANTRELA ER (cialoxine sodium) 250 mg orally once daily with evening meal; maximum dose 500 mg per day.
150 mg orally once daily, may increase to 150 mg twice daily after 3 days if needed. Maximum 300 mg/day.
None Documented
None Documented
Approximately 24 hours (range 20-30 hours) allowing once-daily dosing; steady state reached in 5-7 days.
Terminal half-life of bupropion is approximately 21 hours (±9 hours); for the active metabolite hydroxybupropion, half-life is ~20-27 hours. Steady state reached within 5-8 days.
Primarily renal (70-80% as unchanged drug) with 10-15% biliary/fecal elimination.
Primarily renal (87% as bupropion and its metabolites, with 10% as unchanged drug); 10% fecal.
Category C
Category C
NDRI Antidepressant
NDRI Antidepressant